BRCA mutations
- 10 Dec 2023
- 1 Minute to read
- Print
- PDF
BRCA mutations
- Updated on 10 Dec 2023
- 1 Minute to read
- Print
- PDF
Article summary
Did you find this summary helpful?
Thank you for your feedback
BRCA stands for BReast CAncer gene.
For women with BRCA mutations and no personal history of breast cancer, the current recommendation is that after a prophylactic bilateral salpingo-oophorectomy (BSO) add-back HRT can be prescribed until aged 50 years.
This has not been shown to diminish the risk-reducing benefit of BSO on subsequent risk of breast cancer diagnosis. It should, however, be noted that the clinical data are limited.
References and Further Information:
- Marsden J. British Menopause Society consensus statement: the risks and benefits of HRT before and after a breast cancer diagnosis. Post Reprod Health. 2019.
- Hamoda H, Panay N, Pedder H et al. The British Menopause Society and Women's Health Concern 2020 recommendations on hormone replacement therapy in menpopausal women. Post Reprod Health 2020. Page 190
Was this article helpful?